Camlin Fine Sciences 경영진
경영진 기준 점검 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Ashish Dandekar
최고경영자
₹28.2m
총 보수
| CEO 급여 비율 | 54.61% |
| CEO 재임 기간 | 19.4yrs |
| CEO 지분 보유율 | 10.3% |
| 경영진 평균 재임 기간 | 4.8yrs |
| 이사회 평균 재임 기간 | 5.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 06
532834: Upcoming Capital Decisions Will Support Bullish Outlook Despite Leadership Restructuring
Analysts have trimmed the price target on Camlin Fine Sciences from ₹182.5 to ₹177.5, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly lower fair value estimate. What's in the News Board meeting scheduled for May 26, 2026, to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd AGM on August 11, 2026.내러티브 업데이트 • May 22
532834: Upcoming Capital Decisions Will Support Bullish Outlook With Stable Assumptions
Analysts have kept the price target for Camlin Fine Sciences steady at ₹182.5, with the slight tweaks in discount rate and forward P/E mainly fine tuning their valuation framework rather than signaling a major shift in outlook. What's in the News Board meeting scheduled on May 26, 2026 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).내러티브 업데이트 • Apr 26
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).내러티브 업데이트 • Apr 11
532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).내러티브 업데이트 • Mar 25
532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Mar 10
532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 24
532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).내러티브 업데이트 • Feb 09
532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).내러티브 업데이트 • Jan 25
532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).내러티브 업데이트 • Jan 11
532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.내러티브 업데이트 • Dec 24
532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.내러티브 업데이트 • Dec 10
532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).내러티브 업데이트 • Nov 26
532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.내러티브 업데이트 • Nov 11
532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.새로운 내러티브 • Sep 04
Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -₹274m |
| Dec 31 2025 | n/a | n/a | -₹141m |
| Sep 30 2025 | n/a | n/a | ₹187m |
| Jun 30 2025 | n/a | n/a | ₹825m |
| Mar 31 2025 | ₹28m | ₹15m | ₹685m |
| Dec 31 2024 | n/a | n/a | -₹2b |
| Sep 30 2024 | n/a | n/a | -₹2b |
| Jun 30 2024 | n/a | n/a | -₹1b |
| Mar 31 2024 | ₹29m | ₹15m | ₹651m |
| Dec 31 2023 | n/a | n/a | -₹8m |
| Sep 30 2023 | n/a | n/a | ₹350m |
| Jun 30 2023 | n/a | n/a | ₹674m |
| Mar 31 2023 | ₹26m | ₹14m | ₹577m |
| Dec 31 2022 | n/a | n/a | ₹581m |
| Sep 30 2022 | n/a | n/a | ₹628m |
| Jun 30 2022 | n/a | n/a | ₹442m |
| Mar 31 2022 | ₹20m | ₹12m | ₹650m |
| Dec 31 2021 | n/a | n/a | ₹598m |
| Sep 30 2021 | n/a | n/a | ₹465m |
| Jun 30 2021 | n/a | n/a | ₹579m |
| Mar 31 2021 | ₹18m | ₹11m | ₹510m |
| Dec 31 2020 | n/a | n/a | ₹394m |
| Sep 30 2020 | n/a | n/a | ₹291m |
| Jun 30 2020 | n/a | n/a | ₹302m |
| Mar 31 2020 | ₹18m | ₹11m | ₹303m |
보상 대 시장: Ashish의 총 보수(USD295.68K)는 Indian 시장에서 비슷한 규모 기업의 평균(USD178.96K)보다 높습니다.
보상과 수익: Ashish의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Ashish Dandekar (62 yo)
19.4yrs
재임 기간
₹28,216,000
보수
Mr. Ashish Subhash Dandekar serves as the Chairman of Board at Camlin Fine Sciences Limited since June 17, 2021. He has been the Managing Director of Camlin Fine Sciences Limited (formerly known as Camlin...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & MD | no data | ₹28.22m | 10.34% ₹ 2.6b | |
| MD & Director | 5yrs | ₹24.56m | 1.88% ₹ 481.1m | |
| Executive Director of Technical & Executive Director | no data | ₹11.98m | 0.10% ₹ 26.0m | |
| Chief Financial Officer | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Operating Officer | 2.5yrs | 데이터 없음 | 데이터 없음 | |
| Company Secretary | 4.6yrs | ₹1.39m | 데이터 없음 | |
| Global Head of IT | no data | 데이터 없음 | 데이터 없음 | |
| Management Consultant | no data | 데이터 없음 | 데이터 없음 |
4.8yrs
평균 재임 기간
59.5yo
평균 나이
경험이 풍부한 관리: 532834의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.8 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & MD | 19.4yrs | ₹28.22m | 10.34% ₹ 2.6b | |
| MD & Director | 11.8yrs | ₹24.56m | 1.88% ₹ 481.1m | |
| Executive Director of Technical & Executive Director | 8yrs | ₹11.98m | 0.10% ₹ 26.0m | |
| Independent Director | 1.3yrs | ₹600.00k | 0.068% ₹ 17.4m | |
| Non-Executive Non-Independent Director | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Independent Director | 4.7yrs | ₹2.45m | 데이터 없음 | |
| Non-Executive Non-Independent Director | 8.7yrs | ₹700.00k | 1.57% ₹ 402.5m | |
| Independent Director | 5.8yrs | ₹2.46m | 데이터 없음 | |
| Independent Non-Executive Director | 5.5yrs | ₹2.64m | 0.0031% ₹ 799.2k | |
| Independent Director | 6.8yrs | ₹2.18m | 데이터 없음 | |
| Independent Director | 1.3yrs | ₹125.00k | 데이터 없음 | |
| Non-Executive Non-Independent Director | 1.3yrs | 데이터 없음 | 데이터 없음 |
5.8yrs
평균 재임 기간
60.5yo
평균 나이
경험이 풍부한 이사회: 532834의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/10 13:19 |
| 종가 | 2026/06/10 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Camlin Fine Sciences Limited는 9명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |